Design and rationale of the EVOCATION trial: A prospective, randomized, exploratory study comparing the effect of...

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Periprocedural myocardial infarction (PMI) is a frequent complication of percutaneous coronary intervention (PCI) in stable coronary artery disease (CAD).
• Statin therapy can mitigate PMI by preventing coronary microvascular dysfunction, but its efficacy is limited in some patients.
• The potential of potent lipid-lowering agents like evolocumab to reduce microvascular damage post-PCI remains unexplored.

Purpose of the Study:

• To evaluate the efficacy of evolocumab pretreatment in reducing microvascular damage after PCI.
• To assess the impact of evolocumab on the index of microvascular resistance (IMR) in patients with stable CAD undergoing PCI.
• The EVOCATION trial aims to determine if evolocumab can diminish periprocedural microvascular dysfunction.

Main Methods:

• A multicenter, randomized, open-label, active-controlled, exploratory clinical study (EVOCATION trial).
• 100 patients with stable CAD and high LDL-C despite maximal statin therapy were enrolled.
• Patients received either standard care plus evolocumab or standard care alone for 2-6 weeks prior to PCI.

Main Results:

• The primary endpoint was the index of microvascular resistance (IMR) measured after PCI.
• The study assessed the reduction in microvascular damage as indicated by IMR.
• Results will elucidate the effect of evolocumab on periprocedural microvascular function.

Conclusions:

• The EVOCATION trial will provide crucial insights into the role of evolocumab in managing PMI.
• Findings may support the use of evolocumab as an adjunct therapy to reduce cardiovascular events in PCI patients.
• This study could establish a new therapeutic strategy for preventing microvascular complications during PCI.